Drug Profile
Research programme: cancer gene therapies - Alfacell
Latest Information Update: 26 Jan 2007
Price :
$50
*
At a glance
- Originator Alfacell Corporation
- Class
- Mechanism of Action Mitosis inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Oct 1998 Preclinical trials in Cancer in USA (unspecified route)